From 11:00 pm to 12:00 pm EST ( 8:00 pm to 9:00 pm PST ) on January 6th, the website will be under maintenance. We are sorry for the inconvenience. Please arrange your schedule properly.
Utatrectinib (AZD-7451) is a potent, selective and orally active Trk inhibitor. Utatrectinib blocks TrkC activation and associated tumorigenic behaviors .
TrkC-IN-1 (Compound 6c) is an inhibitor of TrkC. The IC50 values for EBC-1 and HT-29 cells are 3.3-7.1 and 7.3-10.2 μΜ, respectively. TrkC-IN-1 is expected to be used in the research of the anti-cancer field .
LPM4870108 is a potent and orally active pan-Trk (WT and MT) inhibitor, with IC50s of 0.2 nM, 2.4 nM, 3.5 nM and 2.3 nM for TrkC, TrkA, TrkA G595R and TrkA G667C, respectively. LPM4870108 shows selectivity for Trk over ALK (IC50=182 nM). LPM4870108 exhibits anti-tumor activity .
TRK-IN-23 (compound 24b) is a potent and orally active TRK inhibitor with IC50 values of 0.5 nM, 9 nM, 14 nM, 4.4 nM, and 4.8 nM against TRKA, TRKC, TRKA G595R, TRKA F589L, and TRKA G667C, respectively. TRK-IN-23 indues apoptosis of Ba/F3-TRKAG595Rand Ba/F3-TRKAG667C cells .
Ntrk3 Rat Pre-designed siRNA Set A contains three designed siRNAs for Ntrk3 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
Ntrk3 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Ntrk3 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
Pan-Trk-IN-3 (Compound 11g) is a potent inhibitor of pan-Trk and their drug-resistant mutants with IC50 values of 2, 3, 2, 21, 26, 5, 7 and 6 nM against TrkA, TrkB, TrkC, TrkA G595R, TrkA G667C, TrkA G667S, TrkA F589L and TrkCG623R, respectively. Pan-Trk-IN-3 displays excellent antitumor activity and induces apoptosis .
GNF-8625 is a broad-spectrum TRK inhibitor that can combine with Thalidomide to form a PROTAC degrader. The IC50 of GNF-8625 for inhibiting TRKA, TRKB, and TRKC are 0.8 nM, 22 nM, and 5.4 nM, respectively.
PF-06737007 is a potent pan-Trk inhibitor in cell-based assays with
IC50s of 7.7 nM, 15 nM and 3.9 nM for TrkA, TrkB and TrkC, respectively . Anti-hyperalgesic effect .
PF-06733804 is a potent pan-Trk inhibitor in cell-based assays with
IC50s of 8.4 nM, 6.2 nM and 2.2 nM for TrkA, TrkB and TrkC, respectively . Anti-hyperalgesic effect .
TrkA-IN-10 (PI-15R) is a TrkA inhibitor with the IC50 values of 17 nM, 8 nM, and 5 nM for TrkA, TrkB and TrkC, respectively. TrkA-IN-10 can be used in cancer research .
NTRK3 Human Pre-designed siRNA Set A contains three designed siRNAs for NTRK3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Selitrectinib (Standard) is the analytical standard of Selitrectinib. This product is intended for research and analytical applications. Selitrectinib (LOXO-195) is a next-generation TRK kinase inhibitor, with IC50s of 0.6 nM and <2.5 nM for TRKA and TRKC, respectively .
PF-6683324 (Trk-IN-4) is a potent pan-Trk inhibitor in cell-based assays with
IC50s of 1.9 nM, 2.6 nM and 1.1 nM for TrkA, TrkB and TrkC, respectively . Anti-hyperalgesic effect .
(3aR)-Selitrectinib ((3aR)-LOXO-195) is an isform of Selitrectinib (HY-101977), which is a next-generation TRK kinase inhibitor, with IC50s of 0.6 nM and <2.5 nM for TRKA and TRKC, respectively .
TrkA-IN-3 is a potent, subselective and allosteric TrkA inhibitor, with an IC50 of 22.4 nM. TrkA-IN-3 shows more than 8000-fold selectivity for TrkA over TrkB and TrkC. TrkA-IN-3 can be used for the research of pain .
Type II TRK inhibitor 1 is a potent TRK inhibitor, which inhibits various TRK fusion protein variants and wild type. Type II TRK inhibitor 1 exhibits antiproliferative activity against Ba/F3 cells harboring CD74-TRKA G667C and ETV6-TRKCG696C fusion proteins with IC50s of 6 nM and 1.7 nM, respectively . Type II TRK inhibitor 1 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
Trk-IN-8 is a potent TRK inhibitor with IC50s of 0.42, 0.89 and 1.5 nM for TRKAa, TRKA(G595R) and TRKC(G623R), respectively (WO2021115401A1, compound 3) .
GNF-5837 is a potent, selective, and orally bioavailable pan-tropomyosin receptor kinase (TRK) inhibitor which display antiproliferative effects in cellular Ba/F3 assays ( IC50 values of 7 nM, 9 nM and 11 nM for cells containing the fusion proteins Tel-TrkC, Tel-TrkB and Tel-TrkA, respectively) .
RIPK1-IN-7 is a potent and selective RIPK1 inhibitor with a Kd of 4 nM and an enzymatic IC50 of 11 nM. RIPK1-IN-7 exhibits excellent antimetastasis activity in the experimental B16 melanoma lung metastasis model .
Tyrphostin AG 879 (AG 879) is a tyrosine kinase inhibitor that inhibits TrKA phosphorylation (IC50 of 10 μM), but not TrKB and TrKC. Tyrphostin AG 879 is also a selective ErbB2 tyrosine kinase inhibitor with an IC50 of 1 μM, and has at least 500-fold higher selectivity to ErbB2 than EGFR. Tyrphostin AG 879 has anticancer activity .
NMS-P626 is an inhibitor of TRKA, TRKB, and TRKC, with IC50 values of 8 nM, 7 nM, and 3 nM, respectively. NMS-P626 inhibits the growth of KM12 cells by suppressing the phosphorylation of TPM3-TRKA and downstream signaling in KM12 cells, with an IC50 of 19 nM for KM12 cells. NMS-P626 can be used in colorectal cancer research .
Trk-IN-7 (compound I-6) is a potent TRK inhibitor with IC50s of ranging from 0.25-10 nM for TRKA, TRKB and TRKC, respectively. Trk-IN-7 shows inhibition against EML4-ALK (IC50<15 nM) ALK G1202R, ALK C1156Y, ALK R1275Q, ALK F1174L, ALK L1197M, and ALK G1269A (IC50=5-50 nM) .
TRK-IN-30 (Compound C11) is the inhibitor for tropomyosin receptor kinase (TRK) that inhibits TRKA, TRKB and TRKC and drug resistant mutant TRKA G595R with an IC50 of 1.8, 0.98, 3.8, and 54 nM, respectively. TRK-IN-30 inhibits the activation of the downstream PI3K/AKT and MEK/ERK signaling pathways. TRK-IN-30 inhibits the colony formation and cell migration of Km-12, arrests the cell cycle at G0/G1 phase, and induces apoptosis in Km-12 .
TRK-IN-24 (compound 10g) is a Trk Receptor inhibitor that inhibits TRKA, TRKC, TRKA G595R, TRKA G667C and TRKA F589LIC50s are 5.21, 4.51, 6.77, 1.42 and 6.13 nM respectively. TRK-IN-24 has antitumor efficacy in BaF3-CD74-NTRK1 G595R and BaF3-CD74-NTRK1 G667C xenograft models. TRK-IN-24 inhibits the proliferation of Ba/F3 cells transfected with single mutants such as SF, GK, and xDFG, with an IC50 of 1.43-47.56 nM .
JND4135 is a Type II TRK inhibitor with IC50 values of 2.79, 3.19, and 3.01 nM against TRKA, TRKB, TRKC, respectively. JND4135 can overcome resistance from TRK xDFG and other mutant forms in the BaF3 stable model, inhibiting phosphorylation of both WT and xDFG mutant TRKs, along with their downstream signaling molecules. JND4135 can induce G0/G1 phase arrest and apoptosis in BaF3–CD74-TRKA-G667C cells. JND4135 shows tumor growth inhibition activity in the BaF3-CD74-TRKA-G667C mouse xenograft model .
TrkC Protein, a receptor tyrosine kinase, crucially contributes to nervous system and potential heart development. Upon NTF3/neurotrophin-3 binding, TrkC undergoes autophosphorylation, activating pathways like phosphatidylinositol 3-kinase/AKT and MAPK. These pathways regulate cell survival and differentiation, emphasizing TrkC's pivotal role in essential cellular processes during development. TrkC Protein, Human (HEK293, His) is the recombinant human-derived TrkC protein, expressed by HEK293 , with C-His labeled tag.
TrkC Protein, a receptor tyrosine kinase, is vital in nervous system and potential heart development.Upon binding its ligand NTF3/neurotrophin-3, TrkC undergoes autophosphorylation, activating key signaling pathways like phosphatidylinositol 3-kinase/AKT and MAPK.These pathways intricately govern cell survival and differentiation, underscoring TrkC's pivotal role in orchestrating fundamental processes during development.TrkC Protein, Mouse (HEK293, His) is the recombinant mouse-derived TrkC protein, expressed by HEK293 , with C-6*His labeled tag.
TrkC Protein, a receptor tyrosine kinase, crucially contributes to nervous system and potential heart development. Upon NTF3/neurotrophin-3 binding, TrkC undergoes autophosphorylation, activating pathways like phosphatidylinositol 3-kinase/AKT and MAPK. These pathways regulate cell survival and differentiation, emphasizing TrkC's pivotal role in essential cellular processes during development. TrkC Protein, Human (HEK293, His-Fc) is the recombinant human-derived TrkC protein, expressed by HEK293 , with C-hFc, C-His labeled tag.
TrkC Protein, a receptor tyrosine kinase, crucially contributes to nervous system and potential heart development. Upon NTF3/neurotrophin-3 binding, TrkC undergoes autophosphorylation, activating pathways like phosphatidylinositol 3-kinase/AKT and MAPK. These pathways regulate cell survival and differentiation, emphasizing TrkC's pivotal role in essential cellular processes during development. NTRK3 Protein, Human (Biotinylated, sf9, His, Avi) is the recombinant human-derived NTRK3, expressed by Sf9 insect cells , with Avi, His labeled tag. ,
Trk C Antibody (YA5089) is a mouse-derived and non-conjugated monoclonal antibody, targeting to Trk C. It can be applicated for WB, IHC-P, ICC/IF, ELISA assays, in the background of human.
NTRK3 Antibody (YA4307) is a mouse-derived and non-conjugated IgG1 antibody, targeting to NTRK3. It can be applicated for WB, IHC-P, ELISA assays, in the background of human.
NTRK3 Human Pre-designed siRNA Set A contains three designed siRNAs for NTRK3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Ntrk3 Rat Pre-designed siRNA Set A contains three designed siRNAs for Ntrk3 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
Ntrk3 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Ntrk3 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
Inquiry Online
Your information is safe with us. * Required Fields.
